Literature DB >> 9798657

Viral burden and disease progression in HIV-1-infected patients with sickle cell anemia.

O Bagasra1, R M Steiner, S K Ballas, O Castro, G Dornadula, S Embury, D Jungkind, L Bobroski, A Kutlar, S Burchott.   

Abstract

The spleen and lymph nodes are major sites of human immunodeficiency virus type 1 (HIV-1) replication, mutation, and genetic variation in vivo. If a major portion of the lymphatic tissue, such as the spleen, is removed or otherwise is unavailable for invasion by the HIV-1 virus, will the course of the infection be altered, resulting in a prolonged symptom-free interval or even increased survival? The spleen of most adults with sickle cell anemia (SS) is nonfunctional due to recurrent episodes of microinfarction. If autosplenectomized SS patients are exposed to HIV-1, they may be ideal candidates to examine the question of whether absence of splenic function at the time of infection will positively alter the course of HIV-1-related disease. All SS patients with a diagnosis of HIV-1 infection at five university sickle cell centers were included in the patient cohort. Patients in active treatment or in follow-up (group A, n = 11) underwent a series of quantitative viral studies to determine their HIV-1 viral burden. The studies included the branched-DNA signal amplification assay, quantitative DNA-polymerase chain reaction (PCR), quantitative reverse transcription (RT)-initiated-PCR, and in situ PCR. All patients who died of the complications of the acquired immunodeficiency syndrome (AIDS) or of SS, lost to follow-up, or were otherwise unavailable for study (Group B: n = 7) were included in the total patient group. None of the patients in group B underwent quantitative viral studies. In addition, a control population (group C, n = 36) of HIV-1-infected African Americans without SS, of similar age and gender to the SS patients, were compared with the study population for outcomes. In eight of 11 active patients (group A), the CD4+ T-lymphocyte counts were normal and viral burdens were low for an average of 10.25 years following diagnosis. These eight patients all from group A were the only long-term nonprogressors (44%) among a total of 18 SS patients (groups A and B). In group C (control), only five patients of 36 were long-term nonprogressors (13.9%). Five patients (28%) of the total SS group (groups A and B) succumbed to AIDS. One of the five was from Group A. The evaluation of a limited number of adult individuals suggests that a significant proportion of HIV-1-seropositive SS patients (44%) may be asymptomatic long-term nonprogressors. In these patients, the CD4+ T-lymphocyte counts remained high and their viral burdens were remarkably lower than in non-SS HIV-1-seropositive individuals. Whereas this study does not prove an "autosplenectomy" hypothesis, it suggests that in patients with both SS and HIV-1 infection, the retroviral disease may be ameliorated by host factors of which absence of splenic function prior to HIV-1 infection may be one.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798657     DOI: 10.1002/(sici)1096-8652(199811)59:3<199::aid-ajh4>3.0.co;2-l

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

1.  Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in U.S. hospital discharge records: a cross-sectional study.

Authors:  Mehdi Nouraie; Sergei Nekhai; Victor R Gordeuk
Journal:  Sex Transm Infect       Date:  2012-05-24       Impact factor: 3.519

2.  Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease.

Authors:  S R Broussard; S I Staprans; R White; E M Whitehead; M B Feinberg; J S Allan
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Prevalence of serologic markers of transfusion and sexually transmitted infections and their correlation with clinical features in a large cohort of Brazilian patients with sickle cell disease.

Authors:  Paula F Blatyta; Shannon Kelly; Ester Sabino; Liliana Preiss; Franciane Mendes; Anna B Carneiro-Proietti; Daniela de Oliveira Werneck Rodrigues; Rosimere Mota; Paula Loureiro; Claudia Maximo; Miriam Park; Alfredo Mendrone-Jr; Thelma T Gonçalez; Cesar de Almeida Neto; Brian Custer
Journal:  Transfusion       Date:  2019-12-05       Impact factor: 3.157

4.  Increased iron export by ferroportin induces restriction of HIV-1 infection in sickle cell disease.

Authors:  Namita Kumari; Tatiana Ammosova; Sharmin Diaz; Xionghao Lin; Xiaomei Niu; Andrey Ivanov; Marina Jerebtsova; Subhash Dhawan; Patricia Oneal; Sergei Nekhai
Journal:  Blood Adv       Date:  2016-12-27

5.  Role of cellular iron and oxygen in the regulation of HIV-1 infection.

Authors:  Sergei Nekhai; Namita Kumari; Subhash Dhawan
Journal:  Future Virol       Date:  2013-03       Impact factor: 1.831

6.  Viral Load Monitoring in HIV Infection.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

7.  HIV-1 infection in sickle cell disease and sickle cell trait: role of iron and innate response.

Authors:  Sergei Nekhai; Namita Kumari
Journal:  Expert Rev Hematol       Date:  2022-03-24       Impact factor: 2.819

Review 8.  Sickle cell disease: new opportunities and challenges in Africa.

Authors:  J Makani; S F Ofori-Acquah; O Nnodu; A Wonkam; K Ohene-Frempong
Journal:  ScientificWorldJournal       Date:  2013-09-19

9.  A Pathogenic Role for Splenic B1 Cells in SIV Disease Progression in Rhesus Macaques.

Authors:  Gospel Enyindah-Asonye; Anthony Nwankwo; Christopher Hogge; Mohammad Arif Rahman; Sabrina Helmold Hait; Ruth Hunegnaw; Eun-Ju Ko; Tanya Hoang; David J Venzon; Marjorie Robert-Guroff
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

10.  Influence of sickle cell disease on susceptibility to HIV infection.

Authors:  Shannon Kelly; Evan S Jacobs; Mars Stone; Sheila M Keating; Tzong-Hae Lee; Daniel Chafets; John Heitman; Melanie Dimapasoc; Eva Operskalski; Ward Hagar; Elliott Vichinsky; Michael P Busch; Philip J Norris; Brian Custer
Journal:  PLoS One       Date:  2020-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.